Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I/IIa Trial, Marking Key Clinical Milestone
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Clearmind Medicine (CMND) has completed patient enrollment for Part C of its ongoing Phase I/IIa clinical trial evaluating CMND-100.
Part C is a randomized, double-blind, placebo-controlled multiple-dose study assessing safety, tolerability and pharmacokinetics, or how the body processes the drug. Enrollment completion follows enrollment of the first Part B cohort, the first clinical evaluation of CMND-100 in patients with moderate-to-severe Alcohol Use Disorder. Clearmind described earlier Part A safety and tolerability data in healthy volunteers as encouraging.
The trial is being conducted at research sites in the United States and Israel, including Johns Hopkins, Yale, Tel Aviv Sourasky Medical Center and Hadassah Medical Center. The company expects Part C data to deepen its understanding of CMND-100 and help support further development.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointPart C enrollment completed in the ongoing CMND-100 Phase I/IIa trial.
- Moderate pointFirst Part B cohort enrolled, marking CMND-100’s first clinical evaluation in patients with moderate-to-severe Alcohol Use Disorder.
- Minor pointPart A safety and tolerability data in healthy volunteers were described by Clearmind as encouraging.
Negative
- None.
Previous Clinical trial Reports
-
Part C began with six patients enrolled, reported as one-third of enrollment.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
pharmacokinetic medical
randomized medical
double-blind medical
placebo-controlled medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Vancouver, Canada, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the successful completion of patient enrollment for Part C of its ongoing Phase I/IIa clinical trial evaluating CMND-100.
The completion of patient enrollment for Part C marks another important milestone in Clearmind’s clinical development program and reflects the continued strong execution of its Phase I/IIa trial. The achievement follows the successful enrollment of the first cohort in Part B, representing the first clinical evaluation of CMND-100 in patients with moderate-to-severe AUD, and builds on the encouraging safety and tolerability data from Part A in healthy volunteers.
Part C is a randomized, double-blind, placebo-controlled multiple-dose study designed to assess the safety, tolerability, and pharmacokinetic profile of CMND-100. The trial is being conducted at premier clinical research sites across the United States and Israel, including Johns Hopkins University School of Medicine, Yale School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.
“The successful completion of Part C enrollment demonstrates the continued momentum of our CMND-100 program and represents another important milestone for Clearmind,” said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. “The data generated in this cohort is expected to further enhance our understanding of CMND-100’s safety, tolerability, and pharmacokinetic profile to help support the advancement of our proprietary non-hallucinogenic treatment candidate toward future development milestones.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual property portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND."
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the anticipated data from Part C of the Phase I/IIa clinical trial, the potential for such data to further inform the Company’s understanding of CMND-100’s safety, tolerability and pharmacokinetic profile, and the continued clinical development and advancement of CMND-100 toward future development milestones. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.